Ciltacabtagene autoleucel – VJRegenMed

Targeting neoantigens in multiple myeloma with CAR T-cell

Simon Ng — Tue, 12 Apr 2022 11:18:09 +0000

Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapies such as ciltacabtagene autoleucel and idecabtagene vicleucel have made a positive impact on the treatment landscape of multiple myeloma. However, tumor heterogeneity, antigen escape and an immunosuppressive tumor microenvironment are barriers CAR T-cell therapies currently face. Angela Krackhard, MD, PhD, Technical University of Munich, Munich, Germany, describes research on neoantigens and its benefits. As neoantigens are only found in the tumor, off-target effects such as B-cell aplasia and cytokine release syndrome (CRS) are reduced. Utilizing alternative targets such as SLAMF7 and CD38, as well as bispecific CAR T-cells represent novel strategies to optimize immunotherapies for multiple myeloma. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.

Updates in cell and gene therapy approvals

Simon Ng — Wed, 02 Mar 2022 11:58:18 +0000

Bruce Levine, PhD, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, describes recent approvals and developments within the advanced therapy space, including the FDA approval of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR) T-cell therapy, in patients with relapsed/refractory multiple myeloma. Dr Levine additionally highlights developments in tumor-infiltrating lymphocytes (TILs), as well the need to focus on Chemistry, Manufacturing, and Control (CMC) standards within the regulatory process. This interview took place at Advanced Therapies Week 2022.

CAR-T in myeloma: key players in the therapeutic landscape

Marta Palhas — Fri, 26 Feb 2021 14:08:25 +0000

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses CAR T-cell therapy for multiple myeloma. Although the multiple myeloma treatment landscape is rapidly evolving and the development of new therapies has greatly improved outcomes, patients with triple or penta-refractory disease still have limited treatment options. Recently, clinical trials investigating CAR T-cells for multiple myeloma have demonstrated promising clinical activity, showing unprecedented response rates in these heavily pre-treated patient population. Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) are among several BCMA CAR T-cell products in later stages of clinical trials, and it is anticipated that they will be approved in 2021. Prof. Mohty believes that the whole treatment paradigm will see some significant changes in the next five years as CAR T-cells move into earlier lines of therapy. Additionally, Prof. Mohty highlights other immunotherapy strategies, such as BiTEs, as well as novel targets. This interview took place during the 3rd European CAR T-cell Meeting.

Clinical advances with CAR-Ts and bispecifics in R/R myeloma

Marta Palhas — Fri, 26 Feb 2021 14:08:23 +0000

Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, gives an overview of the recent clinical advances with CAR T-cells and bispecifics in relapsed/refractory (R/R) multiple myeloma. Over the past decade, new treatments have transformed survival outcomes of myeloma. However, patients with myeloma refractory to the therapies that currently comprise the hematologic standard of care, including proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies, have limited treatment options. It is expected that additional agents will be available for triple-refractory disease soon. Dr Mateos highlights idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), both BCMA-targeting CAR T-cells. Various bispecific monoclonal antibodies targeting BCMA are currently in development, with promising results. This interview took place during the 3rd European CAR T-cell Meeting.